# LensGen

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lensgen

- Industry: Medical Devices & Equipment
- Headquarters: Irvine, US
- Website: www.lensgen.com
- Total disclosed funding: $23M
- Latest round: Series A (May 1, 2017)
- Investors on record: 3

## About

LensGen, Inc. focuses on developing innovative ophthalmic medical devices, including the Juvene™ Intraocular Lens, aimed at restoring youthful vision and treating age-related eye conditions such as presbyopia and cataracts.Founded in 2012 and headquartered in Irvine, US, LensGen, Inc. specializes in ophthalmic medical devices. The company has successfully completed a total of 7 deals, with its most recent funding round occurring in August 2020, raising USD 10.00 mn in SERIES B funding led by Hoya Corporation. Ramgopal Rao serves as the CEO of the company, which operates independently without known subsidiaries or parent companies.LensGen specializes in ophthalmic medical devices, particularly its flagship product, the Juvene™ Intraocular Lens, which is an investigational device designed to restore youthful vision by mimicking the natural human lens’s ability to change curvature. This product aims to address significant eye conditions such as presbyopia—the age-related loss of the lens’s ability to focus on near objects—and cataracts, which involve the clouding of the natural lens. By utilizing a proprietary design that works in conjunction with the eye's natural accommodation mechanism, the Juvene lens facilitates a continuous range of vision from distance to near, effectively eliminating the need for reading glasses. The company targets a global market, focusing on regions with a high prevalence of cataracts and presbyopia, providing an innovative solution for individuals aged 40 and above who are experiencing these common vision impairments.LensGen operates on a transactional revenue model primarily through partnerships with healthcare providers and surgical centers that perform cataract surgeries. Revenue is generated from the sale of the Juvene™ Intraocular Lens to these medical facilities, which then utilize the product in surgical procedures performed on patients experiencing presbyopia and cataracts. The company's revenue structure is centered on B2B transactions, where healthcare institutions acquire the lens for use in their practices. While specific pricing plans have not been disclosed, the economic framework suggests that revenue is derived from device sales during surgical interventions, aligning with conventional cataract surgery practices, which number over 28 million procedures annually worldwide. This positioning within a high-demand segment of eye care enhances LensGen's market potential as it aims to transform the experience of vision correction.In August 2020, LensGen, Inc. raised USD 10.00 mn in SERIES B funding, which will support the development of new products and expansion into new markets. The company is focused on launching additional innovative ophthalmic devices designed to enhance vision correction capabilities. Future plans include targeting expansion into regions with increasing demands for cataract surgeries and innovative eye care solutions, with specific timelines for market entry yet to be announced.

## Funding rounds

- Series A, May 1, 2017, $21M — Hoya Corporation, Relativity Healthcare Partners
- Seed, Sep 1, 2012, $1.5M — K5 Ventures

## Investors

- K5 Ventures (https://capitalatlas.ai/funds/k5-ventures) — Seed
- Hoya Corporation — Series A
- Relativity Healthcare Partners (https://capitalatlas.ai/funds/relativity-healthcare-partners) — Series A